Table 2 Prevalence of metabolic syndrome components in the four groups at baseline and at follow-up
Metabolic syndrome components | Fatty liver status (n = 1344) | Fatty liver status (n = 112) | Fatty liver status (n = 251) | Fatty liver status (n = 382) | ||||
|---|---|---|---|---|---|---|---|---|
Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
No fatty liver | No fatty liver | Fatty liver | No fatty liver | No fatty liver | Fatty liver | Fatty liver | Fatty liver | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Waist circumference, (men ≥90 cm/women ≥80 cm) | 72 (5.4) | 110 (8.2) | 27 (24.1) | 16 (14.3) | 28 (11.2) | 46 (18.3) | 110 (28.8) | 108 (28.3) |
Triglyceride (TG ≥1.7 mmol/L or drug treatment) | 215 (16.0) | 213 (15.8) | 50 (44.6) | 40 (35.7) | 112 (44.6) | 123 (49.0) | 205 (53.7) | 202 (52.9) |
HDL-C (HDL-C <1 mmol/L (men)/<1.3 mmol/L (women) or drug treatment) | 90 (6.7) | 100 (7.4) | 6 (5.4) | 12 (10.7) | 19 (7.6) | 45 (17.9) | 20 (5.2) | 52 (13.6) |
Blood pressure (BP >130/85 mmHg or drug treatment) | 69 (5.1) | 172 (12.8) | 8 (7.1) | 28 (25.0) | 16 (6.4) | 53 (21.1) | 24 (6.3) | 99 (25.9) |
Glucose (glucose ≥5.6 mmol/L or drug treatment) | 106 (7.9) | 232 (17.3) | 16 (14.3) | 37 (33.0) | 20 (8.0) | 73 (29.1) | 59 (15.4) | 131 (34.3) |
Metabolic syndrome (presence of any three of the following five traits) | 0 (0 %) | 41 (3.1 %) | 0 (0 %) | 10 (8.9 %) | 0 (0 %) | 36 (14.3 %) | 0 (0 %) | 72 (18.8 %) |